Overview

MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma

Status:
Completed
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
This research study is studying a targeted therapy as a possible treatment for merkel cell carcinoma. - The name of the study intervention involved in this study is: MLN0128.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborator:
Millennium Pharmaceuticals, Inc.